CR20130594A - Monohidrato de derivados de aza-adamantano - Google Patents

Monohidrato de derivados de aza-adamantano

Info

Publication number
CR20130594A
CR20130594A CR20130594A CR20130594A CR20130594A CR 20130594 A CR20130594 A CR 20130594A CR 20130594 A CR20130594 A CR 20130594A CR 20130594 A CR20130594 A CR 20130594A CR 20130594 A CR20130594 A CR 20130594A
Authority
CR
Costa Rica
Prior art keywords
monohidrate
aza
adamantan
derivatives
adamantan derivatives
Prior art date
Application number
CR20130594A
Other languages
English (en)
Inventor
Shuang Chen
James J Napier
Geoff G Z Zhang
Paul J Brackemeyer
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44736085&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130594(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of CR20130594A publication Critical patent/CR20130594A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)

Abstract

Forma cristalina monohidrato del citrato diácido de (4s)-4-(5-fenil-1,3,4-tiadiazol-2-iloxi)-1-azatriciclo[3.3.1.13,7]decano, composiciones que comprenden dicho compuesto y un proceso para preparar el compuesto.
CR20130594A 2010-09-23 2013-11-14 Monohidrato de derivados de aza-adamantano CR20130594A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38567410P 2010-09-23 2010-09-23

Publications (1)

Publication Number Publication Date
CR20130594A true CR20130594A (es) 2014-01-31

Family

ID=44736085

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20130169A CR20130169A (es) 2010-09-23 2013-04-15 Monohidrato de derivados de aza-adamantano
CR20130594A CR20130594A (es) 2010-09-23 2013-11-14 Monohidrato de derivados de aza-adamantano

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CR20130169A CR20130169A (es) 2010-09-23 2013-04-15 Monohidrato de derivados de aza-adamantano

Country Status (25)

Country Link
US (2) US9464078B2 (es)
EP (1) EP2619205B1 (es)
JP (2) JP2013537912A (es)
KR (1) KR20130108586A (es)
CN (2) CN106074548A (es)
AR (1) AR083100A1 (es)
AU (1) AU2011305462B2 (es)
BR (2) BR112013005434A2 (es)
CA (1) CA2809675A1 (es)
CL (2) CL2013000756A1 (es)
CO (1) CO6720965A2 (es)
CR (2) CR20130169A (es)
DO (2) DOP2013000064A (es)
EC (1) ECSP13012575A (es)
GT (1) GT201300064A (es)
MX (1) MX2013003344A (es)
NZ (2) NZ707955A (es)
PE (1) PE20131394A1 (es)
PH (1) PH12013500541A1 (es)
RU (2) RU2579121C2 (es)
SG (2) SG2014013460A (es)
TW (2) TW201626996A (es)
UA (1) UA110802C2 (es)
UY (1) UY33628A (es)
WO (1) WO2012040404A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives
US8802693B1 (en) 2011-03-09 2014-08-12 Abbvie Inc. Azaadamantane derivatives and methods of use
US20130317055A1 (en) * 2012-05-24 2013-11-28 Abbvie Inc. Neuronal nicotinic agonist and methods of use
US8969562B2 (en) 2013-03-12 2015-03-03 Abbvie, Inc. Azaadamantane formate ester and process for preparing azaadamantane derivatives
SG11201604786QA (en) * 2013-12-13 2016-07-28 Allergan Inc Polymorphic and amorphous forms of cortisol 17-alpha-benzoate and methods for the preparation and use thereof
EP3623371A1 (en) 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
CA2988968A1 (en) 2015-06-10 2016-12-15 Forum Pharmaceuticals, Inc. Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors
WO2017027600A1 (en) 2015-08-12 2017-02-16 Forum Pharmaceuticals, Inc. GEMINAL SUBSTITUTED AMINOBENZISOXAZOLE COMPOUNDS AS AGONISTS OF α7-NICOTINIC ACETYLCHOLINE RECEPTORS

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2514006A1 (fr) 1981-10-05 1983-04-08 Nativelle Sa Ets Acylamino-4 aza-1 adamantanes, procede pour leur preparation, et application en therapeutique
EP0088484A1 (en) 1982-02-04 1983-09-14 Fbc Limited Herbicidal thiadiazolyl N-aminoureas
GB8523211D0 (en) 1985-09-19 1985-10-23 Beecham Group Plc Compounds
EP0350130A3 (en) 1988-07-07 1991-07-10 Duphar International Research B.V New substituted 1,7-annelated 1h-indazoles
US5260303A (en) 1991-03-07 1993-11-09 G. D. Searle & Co. Imidazopyridines as serotonergic 5-HT3 antagonists
US5385912A (en) 1991-03-08 1995-01-31 Rhone-Poulenc Rorer Pharmaceuticals Inc. Multicyclic tertiary amine polyaromatic squalene synthase inhibitors
CA2105655A1 (en) 1991-03-08 1992-09-09 Kent Neuenschwander Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
US5280028A (en) 1992-06-24 1994-01-18 G. D. Searle & Co. Benzimidazole compounds
US5434151A (en) 1992-08-24 1995-07-18 Cytomed, Inc. Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
US5840903A (en) 1992-07-27 1998-11-24 G. D. Searle & Co. 4-aminomethyl-1-azaadamantane derived benzamides
JP3235913B2 (ja) 1993-07-30 2001-12-04 エーザイ株式会社 アミノ安息香酸誘導体
US5399562A (en) 1994-02-04 1995-03-21 G. D. Searle & Co. Indolones useful as serotonergic agents
US5821370A (en) 1994-10-24 1998-10-13 Eli Lilly And Company Heterocyclic compounds and their preparation and use
US5852037A (en) 1995-11-13 1998-12-22 Eli Lilly And Company Method for treating anxiety
WO1997020819A1 (en) 1995-12-06 1997-06-12 Eli Lilly And Company Composition for treating pain
AU7871498A (en) 1996-12-20 1998-07-17 Novo Nordisk A/S A method of treating hypercholesterolemia and related disorders
US7732163B2 (en) 1997-08-21 2010-06-08 Board Of Trustees Of The University Of Arkansas Extracellular serine protease
US8236500B2 (en) 1997-10-23 2012-08-07 The United States Of America, As Represented By The Department Of Veterans Affairs Promoter variants of the alpha-7 nicotinic acetylcholine receptor
US6875606B1 (en) 1997-10-23 2005-04-05 The United States Of America As Represented By The Department Of Veterans Affairs Human α-7 nicotinic receptor promoter
TR200001338T2 (tr) 1997-11-12 2000-08-21 Bayer Aktiengesellschaft 2-Fenil-ikameli imidazotriazinonlar
US5952339A (en) 1998-04-02 1999-09-14 Bencherif; Merouane Pharmaceutical compositions and methods of using nicotinic antagonists for treating a condition or disorder characterized by alteration in normal neurotransmitter release
CA2317567A1 (en) 1998-04-02 1999-10-14 R.J. Reynolds Tobacco Company Pharmaceutical compositions and methods for use
US5986100A (en) 1998-04-02 1999-11-16 Crooks; Peter Anthony Pharmaceutical compositions and methods for use
US6057446A (en) 1998-04-02 2000-05-02 Crooks; Peter Anthony Certain 1-aza-tricyclo [3.3.1-13,7 ] decane compounds
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
WO1999062505A2 (en) 1998-06-01 1999-12-09 Ortho-Mcneil Pharmaceutical, Inc. Method for treating neurodegenerative disorders
ID27544A (id) 1998-08-18 2001-04-12 Ucb Sa Agonis dan antagonis muskarinat
NZ513575A (en) 1999-05-04 2003-07-25 Neurosearch As Heteroaryl diazabicycloalkanes useful for treating or preventing a disease or a disorder responsive to the activity of nAChR modulators
BR0011534A (pt) 1999-05-24 2002-02-26 Targacept Inc Alquilaminas aril substituìdas capazes de ativação de receptores colinérgicos nicotìnicos
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
WO2001040261A1 (en) 1999-12-01 2001-06-07 Ortho-Mcneil Pharmaceutical, Inc. Method of diagnosing neurodegenerative disease
AU2001257449A1 (en) 2000-05-01 2001-11-12 Targacept, Inc. Imaging of nicotinic acetylcholine receptor subtypes
DE60108639T2 (de) 2000-07-04 2005-07-07 Neurosearch A/S Aryl- und heteroaryldiazabicycloalkane, deren zubereitung und verwendung
AUPR213700A0 (en) 2000-12-18 2001-01-25 Biota Scientific Management Pty Ltd Antiviral agents
US7112593B2 (en) 2001-03-27 2006-09-26 Eisai Co., Ltd. N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient
EP1425577A4 (en) 2001-08-10 2004-12-29 Symyx Technologies Inc APPARATUSES AND METHODS FOR PREPARING AND TESTING PRE-FORMULATIONS AND CORRESPONDING SYSTEMS
FR2832713B1 (fr) 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
AU2002360598B2 (en) 2001-12-14 2008-02-14 Medical College Of Georgia Research Institute, Inc. Methods and compositions for treatment of central nervous system disorders
ATE348831T1 (de) 2002-05-07 2007-01-15 Neurosearch As Diazabicyclische biarylderivate
US7049374B2 (en) 2002-07-18 2006-05-23 Chevron U.S.A. Inc. Heterodiamondoids
MXPA05001702A (es) 2002-08-14 2005-04-19 Neurosearch As Derivados de quinuclidina novedosos y su uso.
US7030112B2 (en) 2003-03-25 2006-04-18 Bristol-Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
ES2359408T3 (es) 2003-04-16 2011-05-23 Merck Serono Sa Uso de slurp-1 para tratar enfermedades relacionadas con la disfunción de receptores de acetilcolina.
US7202363B2 (en) 2003-07-24 2007-04-10 Abbott Laboratories Thienopyridine and furopyridine kinase inhibitors
WO2005020921A2 (en) 2003-08-29 2005-03-10 Exelixis, Inc. C-kit modulators and methods of use
US20050065178A1 (en) 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
US7399765B2 (en) 2003-09-19 2008-07-15 Abbott Laboratories Substituted diazabicycloalkane derivatives
TWI331154B (en) 2003-11-12 2010-10-01 Solvay Pharm Gmbh Novel 17-hydroxysteroid dehydrogenase type i inhibitors
JP2005232071A (ja) 2004-02-19 2005-09-02 Kanto Chem Co Inc ピラゾール誘導体
WO2005111003A1 (en) 2004-04-29 2005-11-24 Abbott Laboratories Amino-tetrazoles analogues and methods of use
CN1964956B (zh) 2004-05-24 2013-03-27 安美基公司 11-β-羟基类固醇脱氢酶1型的抑制剂
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
WO2006012395A2 (en) 2004-07-23 2006-02-02 Susan Marie Royalty Peptidase inhibitors
CN104958270A (zh) 2004-08-25 2015-10-07 伊森舍丽斯有限公司 钾atp通道开放剂的药物制剂及其应用
US7652010B2 (en) 2004-10-15 2010-01-26 Neurosearch A/S Azabicyclic aryl derivatives and their medical use
CA2584838A1 (en) 2004-10-20 2006-05-04 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
AU2004325725A1 (en) 2004-12-10 2006-06-22 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
US8906360B2 (en) 2005-07-22 2014-12-09 The Board Of Trustees Of The Leland Stanford Junior University Light-activated cation channel and uses thereof
US9274099B2 (en) 2005-07-22 2016-03-01 The Board Of Trustees Of The Leland Stanford Junior University Screening test drugs to identify their effects on cell membrane voltage-gated ion channel
US7897766B2 (en) 2005-09-23 2011-03-01 Abbott Laboratories Amino-aza-adamantane derivatives and methods of use
US8173658B2 (en) 2005-12-06 2012-05-08 Neurosearch A/S Diazabicycylic aryl derivatives and their medical use
US20090291976A1 (en) 2006-06-27 2009-11-26 Peter Andrew Ferchmin Neuronal circuit-dependent neuroprotection by interaction between nicotinic receptors
FR2905009A1 (fr) 2006-08-18 2008-02-22 Servier Lab Methode de criblage de composes aux proprietes anti-amyloide
US20100234349A1 (en) 2006-09-04 2010-09-16 Olsen Gunnar M Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer
BRPI0718437A2 (pt) 2006-10-27 2013-11-19 Medivation Neurology Inc Métodos e terapias de combinação para tratar a doença de alzheimer usando, entre outros, dimebon e dolepezil
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
CN101541792A (zh) * 2006-11-06 2009-09-23 艾博特公司 氮杂金刚烷衍生物和应用方法
US8314119B2 (en) * 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
BRPI0806972A2 (pt) 2007-02-09 2014-04-08 Astellas Pharma Inc Composto cíclico contendo ponte azo
WO2008106694A2 (en) 2007-03-01 2008-09-04 The Board Of Trustees Of The Leland Stanford Junior University Systems, methods and compositions for optical stimulation of target cells
US20100144538A1 (en) 2007-03-08 2010-06-10 Genizon Biosciences Inc. Genemap of the human genes associated with schizophrenia
WO2008118742A1 (en) 2007-03-23 2008-10-02 Abbott Laboratories Azaadamantane ester and carbamate derivatives and methods of use thereof
ES2521494T3 (es) 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
WO2009017454A1 (en) 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of a gsk3 inhibitor and an a7-nicotinic agonist 960
SA08290475B1 (ar) 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
WO2009058120A1 (en) 2007-11-02 2009-05-07 Sri International Nicotinic acetylcholine receptor modulators
US8697722B2 (en) 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
WO2009066735A1 (ja) 2007-11-20 2009-05-28 Nissan Chemical Industries, Ltd. ２－アザアダマンタン類の製造方法
DE102007058504A1 (de) 2007-12-05 2009-07-09 Acino Ag Transdermales therapeutisches System mit einem Gehalt an einem Modulator für nikotinische Acetylcholinrezeptoren (nAChR)
EP2254598B1 (en) 2008-02-13 2013-07-10 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
US20090239901A1 (en) 2008-03-19 2009-09-24 Merouane Bencherif Method and compositions for treatment of cerebral malaria
WO2009140201A1 (en) 2008-05-12 2009-11-19 Targacept, Inc. Methods for preventing the development of retinopathy by the oral administration of nnr ligands
FR2931677B1 (fr) 2008-06-02 2010-08-20 Sanofi Aventis Association d'un agoniste partiel des recepteurs nicotiniques et d'un inhibiteur d'acetylcholinesterase, composition la contenant et son utilisation dans le traitement des troubles cognitifs
US20110097324A1 (en) 2008-06-13 2011-04-28 Centre For Addiction And Mental Health Compositions and methods for modulating nicotinic/nmda receptor function
CA2736871C (en) 2008-09-11 2019-03-12 Catholic Healthcare West Nicotinic attenuation of cns inflammation and autoimmunity
WO2010042799A2 (en) 2008-10-09 2010-04-15 Howard Hughes Medical Institute Novel chimeric ligand-gated ion channels and methods of use thereof
CN102209540A (zh) 2008-11-11 2011-10-05 塔加西普特公司 使用α7-选择性配体的治疗方法
WO2010088400A1 (en) 2009-01-28 2010-08-05 Catholic Healthcare West Methods of diagnosing and treating neurodegenerative diseases
US20120149691A1 (en) 2009-07-31 2012-06-14 Biocryst Pharmaceuticals, Inc. Pyrrolo [1,2-b] Pyridazine Derivatives as Janus Kinase Inhibitors
US20120237563A1 (en) 2009-08-21 2012-09-20 University Of Florida Research Foundation Inc. Controlled-release formulations of anabaseine compounds and uses thereof
WO2011044537A2 (en) 2009-10-09 2011-04-14 Afraxis, Inc. Methods for treating alzheimer's disease
WO2011058582A1 (en) 2009-11-16 2011-05-19 Orchid Research Laboratories Ltd. Histone deacetylase inhibitors for the treatment of fungal infections
US9464078B2 (en) 2010-09-23 2016-10-11 Abbvie Inc. Monohydrate of azaadamantane derivatives
EP2441755A1 (en) 2010-09-30 2012-04-18 Almirall, S.A. Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors
WO2012059932A1 (en) 2010-11-01 2012-05-10 Aurigene Discovery Technologies Limited 2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors

Also Published As

Publication number Publication date
WO2012040404A1 (en) 2012-03-29
CL2013000756A1 (es) 2013-07-12
UA110802C2 (uk) 2016-02-25
BR122014023207A2 (pt) 2019-05-28
JP2017039764A (ja) 2017-02-23
EP2619205A1 (en) 2013-07-31
AU2011305462B2 (en) 2015-11-26
KR20130108586A (ko) 2013-10-04
CO6720965A2 (es) 2013-07-31
NZ609761A (en) 2015-10-30
CR20130169A (es) 2013-06-12
CN103180321A (zh) 2013-06-26
CL2014000651A1 (es) 2014-09-05
RU2579121C2 (ru) 2016-03-27
CA2809675A1 (en) 2012-03-29
RU2013118560A (ru) 2014-10-27
GT201300064A (es) 2014-07-11
PH12013500541A1 (en) 2013-05-06
TW201212914A (en) 2012-04-01
BR112013005434A2 (pt) 2016-06-07
JP2013537912A (ja) 2013-10-07
EP2619205B1 (en) 2017-05-17
UY33628A (es) 2012-03-30
US9464078B2 (en) 2016-10-11
US20150239882A1 (en) 2015-08-27
SG188307A1 (en) 2013-04-30
CN106074548A (zh) 2016-11-09
DOP2013000249A (es) 2014-01-15
NZ707955A (en) 2016-03-31
AR083100A1 (es) 2013-01-30
PE20131394A1 (es) 2014-01-11
TW201626996A (zh) 2016-08-01
DOP2013000064A (es) 2013-07-15
MX2013003344A (es) 2013-06-28
RU2016105706A (ru) 2018-11-22
SG2014013460A (en) 2014-09-26
ECSP13012575A (es) 2013-07-31
US20120245195A1 (en) 2012-09-27
AU2011305462A1 (en) 2013-03-21

Similar Documents

Publication Publication Date Title
ECSP13012575A (es) Monohidrato de derivados de aza-adamantano
BR112012033278A2 (pt) composições de éster de celulose/elastômero, artigo, e, processo para produzir uma composição de éster de celulose/elastômero
PH12016501375A1 (en) Pyridin-2-amides useful as cb2 agonists
MX2010012298A (es) Activadores de glucocinasa.
MY150542A (en) Cmet inhibitors
MX378354B (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
CR20140546A (es) Forma cristalina a de 1,5-dimetil-6-tioxo-3- (2,2,7-trifluoro- 3-oxo-4- (prop-2-inil)-3,4-dihidro -2h-benzo [b] [1,4] oxazin-6-il)-1,3,5- triazinan-2,4-diona
MX2014005803A (es) Composiciones de ester de celulosa/elastomero.
CL2012000311A1 (es) Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales.
GT201400111A (es) Triazolopiridinas sustituidas
CL2012003491A1 (es) Compuesto derivado de dihidropirrol sustituidos; proceso para preparar dichos derivados en forma estereoselectiva.
CL2013001221A1 (es) Compuesto clorhidrato de (4a-r, 9a-s)-1-(1h-benzoimidazol-5-carbonil-2,3,4,4a,9,9a-hexahidro-1 h-inden[2,1-b] piridin-6-carbonitrilo y sus formas cristalinas i y ii, inhibidores de hsd 1; composicion farmaceutica; metodo para producir la forma cristalina i del compuesto; metodo para producir la forma cristalina ii del compuesto.
EP3404032A3 (en) Process for making benzoxazepin compounds
EA201890075A1 (ru) Инъецируемые фармацевтические композиции лефамулина
AR093738A1 (es) Formas solidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos
CL2011003123A1 (es) Compuestos derivados de ciclopentanamida sustituidos; composicion farmaceutica; proceso de obtencion; y uso en el tratamiento o la profilaxis de la diabetes, aterosclerosis, entre otras.
GB201020397D0 (en) Compounds
MX2015016766A (es) Nuevos derivados de tetrazolona.
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
CO7200259A2 (es) Nuevos derivados de piridina
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen
CL2012000350A1 (es) Combinacion farmaceutica que comprende un compuesto derivado de bifenilamida y un agente inhibidor de bcr-abl seleccionado de nilotinib; composicion farmaceutica; y uso de la combinacion para el tratamiento de leucemia positiva a bcr-abl.
TW201612188A (en) The L-proline complex, monohydrate and crystal of a sodium-glucose contransporter 2 inhibitor
ECSP11011150A (es) Derivados de arilciclopropilacetamida útiles como activadores de glucoquinasa
EA201400882A1 (ru) Способ стереоселективного синтеза 9-гидрокси-5-оксо-1,4-диазаспиро[5.5]ундеканов, содержащих защитные группы в 1,4-положениях